Launching in the Nordics non-prescription erectile dysfunction treatment Eroxon helped drive up sales at Norway’s Navamedic in the second quarter.
Navamedic Benefits From Eroxon Launch In Nordics
OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.
More from Europe
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
More from Innovation & IP
• By
In its first health claim assessment of 2025, the European Commission has rejected an application by Sweden's Greenleaf for its Appethyl supplement.
• By
Biotech identifying and stabilizing RNA compounds that can be incorporated into dietary supplements will receive mentorship, strategy guidance and technical support from experts at Nestlé Health Science.
• By
With the acquisition of HKS Health Solutions, 1Q Health Group states its ambition to be the leading full-service CDMO in Europe. Separately, Italy's Ourvita enhances its capabilities through a deal for Poland's Laboratoria Natury.